Get the Stockscreener App
1.01
0.98%
-0.01
After Hours:
1.02
0.01
+0.99%
Fibrobiologics Inc stock is traded at $1.01, with a volume of 68,191.
It is down -0.98% in the last 24 hours and up +7.86% over the past month.
FibroBiologics Inc is a clinical-stage cell therapy company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with unmet medical needs, including degenerative disc disease, multiple sclerosis, wound healing, and certain cancers, and potential extension of life applications including thymic and splenic involution reversal.
See More
Previous Close:
$1.02
Open:
$1.05
24h Volume:
68,191
Relative Volume:
0.23
Market Cap:
$46.68M
Revenue:
-
Net Income/Loss:
$-17.78M
P/E Ratio:
-1.839
EPS:
-0.5492
Net Cash Flow:
$-10.52M
1W Performance:
-17.21%
1M Performance:
+7.86%
6M Performance:
-68.24%
1Y Performance:
-84.97%
1-Day Range:
$1.00
$1.05
1-Week Range:
$0.9484
$1.2691
52-Week Range:
$0.7626
$13.59
Fibrobiologics Inc Stock (FBLG) Company Profile
Name
Fibrobiologics Inc
Sector
Industry
Phone
281-671-5150
Address
455 E. MEDICAL CENTER BLVD, HOUSTON
Compare FBLG with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FBLG
Fibrobiologics Inc
|
1.01 | 46.68M | 0 | -17.78M | -10.52M | -0.5492 |
|
VRTX
Vertex Pharmaceuticals Inc
|
501.15 | 126.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.61 | 65.06B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
649.67 | 37.54B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
259.39 | 32.56B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
255.77 | 26.40B | 3.81B | -644.79M | -669.77M | -6.24 |
Fibrobiologics Inc Stock (FBLG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-12-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-30-24 | Initiated | H.C. Wainwright | Buy |
| Sep-24-24 | Initiated | Maxim Group | Buy |
Fibrobiologics Inc Stock (FBLG) Latest News
FibroBiologics Presents at the ThymUS 2025 Meeting - GlobeNewswire
FibroBiologics Research Scientist Presents Innovative Thymus Organoid Development at ThymUS 2025 Meeting - Nasdaq
Revolutionary Thymus Organoid Breakthrough: FibroBiologics Reveals New T-Cell Generation Method - Stock Titan
FibroBiologics, Inc. (NASDAQ:FBLG) Shares Acquired by Cerity Partners LLC - Defense World
FibroBiologics Inc Inc. (FBLG) Price Performance: A Technical Analysis Perspective - investchronicle.com
O Shaughnessy Asset Management LLC Acquires New Position in FibroBiologics, Inc. (NASDAQ:FBLG) - Defense World
Raymond James Financial Inc. Invests $37,000 in FibroBiologics, Inc. (NASDAQ:FBLG) - Defense World
FibroBiologics’ (FBLG) Buy Rating Reiterated at D. Boral Capital - Defense World
FibroBiologics to Present at The Cell & Gene Meeting on the Mediterranean - GlobeNewswire
Revolutionary Cell Therapy: FibroBiologics Unveils Multi-Disease Treatment Platform in Rome - Stock Titan
Houston Biotechnology Company Brings Manufacturing Ops Home With New Facility - Bisnow
Fibrobiologics stock plunges to 52-week low at $0.8 amid market challenges By Investing.com - Investing.com South Africa
Fibrobiologics stock plunges to 52-week low at $0.8 amid market challenges - Investing.com India
FibroBiologics opens cell therapy manufacturing space ahead of clinical trials - The Business Journals
OTC Markets Hosts Virtual Investor Presentation with Pete O'Heeron, CEO & Chairman of FibroBiologics, Inc., with David Bautz, PhD, Senior Analyst at Zacks SCR - Yahoo Finance
FibroBiologics opens new lab to boost chronic disease research By Investing.com - Investing.com South Africa
FibroBiologics opens new lab to boost chronic disease research - Investing.com
FibroBiologics announces opening of new lab facility - TipRanks
FibroBiologics Unveils New and Expanded Houston Laboratory Space to Pursue Innovation and Breakthroughs in Fibroblast-Based Therapeutics - The Manila Times
FibroBiologics Unveils New and Expanded Houston Laboratory - GlobeNewswire
FibroBiologics Supercharges R&D with Massive New Lab Launch: In-House Manufacturing Next - Stock Titan
Zacks Small Cap Weighs in on FibroBiologics Q1 Earnings - Defense World
FY2025 EPS Estimates for FibroBiologics Increased by Analyst - Defense World
FBLG: Phase 1/2 Trial in Diabetic Foot Ulcers to Initiate in 2Q25… - Zacks Small Cap Research
HC Wainwright Comments on FibroBiologics Q1 Earnings - Defense World
FibroBiologics gibt wissenschaftlicher Fortschritte bei der Reparatur von Hirngewebe bekannt - GlobeNewswire Inc.
FibroBiologics Announces Scientific Advancement in Confirmation Results of Brain Tissue Repair - GlobeNewswire
FibroBiologics announces advancement in results of brain tissue repair - TipRanks
Fibrobiologics Announces Scientific Advancement In Confirmation Results Of Brain Tissue Repair - MarketScreener
Major Breakthrough: FibroBiologics Confirms Brain Tissue Regeneration Success - Stock Titan
FibroBiologics’ (FBLG) “Buy” Rating Reaffirmed at D. Boral Capital - Defense World
Virtu Financial LLC Buys New Holdings in FibroBiologics, Inc. (NASDAQ:FBLG) - Defense World
FibroBiologics’ (FBLG) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Fibrobiologics stock plunges to 52-week low at $0.93 amid market challenges By Investing.com - Investing.com South Africa
Fibrobiologics stock plunges to 52-week low at $0.93 amid market challenges - Investing.com Canada
FibroBiologics Reports Full Year 2024 Financial Results and Provides Corporate Update - The Manila Times
FibroBiologics Slashes Annual Losses by $5.3M as Key Clinical Trial Approaches - Stock Titan
Spotting Winners: TopBuild (NYSE:BLD) And Home Builders Stocks In Q4 - The Globe and Mail
FibroBiologics Announces 2025 Annual Meeting of Stockholders - GlobeNewswire
Biotech Pioneer FibroBiologics Reveals Massive 160+ Patent Portfolio at Upcoming Shareholder Meeting - Stock Titan
Applied Industrial (AIT): Buy, Sell, or Hold Post Q4 Earnings? - The Globe and Mail
3 Reasons to Avoid FUBO and 1 Stock to Buy Instead - The Globe and Mail
Intuitive Machines Stock (LUNR) Lifts Off with 30% Surge Post Q4 Results - The Globe and Mail
FibroBiologics to Present at The German-Nordic Joint Extracellular Matrix Meeting - GlobeNewswire
FibroBiologics Announces Presentation on Innovative Fibroblast-Based Therapeutics at The German-Nordic Joint Extracellular Matrix Meeting - Nasdaq
FBLG stock touches 52-week low at $0.98 amid sharp annual decline By Investing.com - Investing.com South Africa
FBLG stock touches 52-week low at $0.98 amid sharp annual decline - Investing.com Australia
Fibrobiologics Inc Stock (FBLG) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.47%
2.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):